Keyphrases
Statins
100%
Monotherapy
100%
Combination Therapy
100%
Lipid-lowering Agents
100%
Low Intensity
40%
Clinical Benefit
30%
Atherosclerotic Cardiovascular Disease (ASCVD)
30%
Low-density Lipoprotein Cholesterol Level
30%
High Risk
20%
Ezetimibe
20%
MEDLINE
20%
Bile Acid Sequestrants
20%
Type 1 Diabetes Mellitus (T1DM)
10%
Population Characteristics
10%
Randomized Controlled Trial
10%
Adverse Events
10%
Absence of Evidence
10%
Risk of Bias
10%
Embase
10%
3 Fatty Acids
10%
Data Extraction
10%
Data Synthesis
10%
Clinical High Risk
10%
Intolerant
10%
Attrition Rate
10%
Low-density Lipoprotein Cholesterol (LDL-C)
10%
Cochrane Central Register of Controlled Trials
10%
Cardiovascular Disease Events
10%
Niacin
10%
Non-statins
10%
Population Interventions
10%
Fibrates
10%
Long-term Clinical Outcome
10%
Population Outcomes
10%
High-intensity Statin
10%
Pharmacology, Toxicology and Pharmaceutical Science
Statin (Protein)
100%
Combination Therapy
100%
Monotherapy
100%
Low Density Lipoprotein Cholesterol
40%
Coronary Artery Atherosclerosis
30%
Ezetimibe
20%
Bile Acid Sequestrant
20%
Adverse Event
10%
Hyperlipidemia
10%
Diabetes Mellitus
10%
Randomized Controlled Trial
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Fatty Acid
10%
Nicotinic Acid
10%
Fibric Acid Derivative
10%
Medicine and Dentistry
Combination Therapy
100%
Monotherapy
100%
Statin
100%
Low Density Lipoprotein Cholesterol
36%
Bile Acid Sequestrant
18%
Ezetimibe
18%
Diabetes Mellitus
9%
Hyperlipidemia
9%
Drug Therapy
9%
Clinician
9%
Randomized Controlled Trial
9%
Adverse Event
9%
Fatty Acid
9%
Population and Population Related Phenomena
9%
Niacin
9%
Independent Reviewer
9%
Nursing and Health Professions
Bile Acid Sequestrant
20%
Ezetimibe
20%
Fibric Acid Derivative
10%